Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Microorganisms
Main Authors: Sada, Mitsuru, Saraya, Takeshi, Ishii, Haruyuki, Okayama, Kaori, Hayashi, Yuriko, Tsugawa, Takeshi, Nishina, Atsuyoshi, Murakami, Koichi, Kuroda, Makoto, Ryo, Akihide, Kimura, Hirokazu
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7589801/
https://ncbi.nlm.nih.gov/pubmed/33092045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/microorganisms8101610
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados